Related references
Note: Only part of the references are listed.Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
Ralph A. DeFronzo
DIABETES OBESITY & METABOLISM (2017)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Martin Lorenz et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Combination therapy for type 2 diabetes: dapagliflozin plus metformin
Xueying Tan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial
Vasilios G. Athyros et al.
CURRENT VASCULAR PHARMACOLOGY (2016)
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
Michael Nauck et al.
DIABETES CARE (2016)
Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
C. F. Deacon et al.
DIABETES OBESITY & METABOLISM (2016)
New fixed dose chemical combinations: the way forward for better diabetes type II management?
Suhaj Abdulsalim et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction
Wei-Ren Chen et al.
ENDOCRINE (2016)
Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel
Christoph Kapitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Effects of glucagon-like peptide-1 agents on left ventricular function: Systematic review and meta-analysis
Rui Liu et al.
ANNALS OF MEDICINE (2014)
The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
Carsten F. Gotfredsen et al.
DIABETES (2014)
Therapies for inter-relating diabetes and obesity - GLP-1 and obesity
Eva W. Iepsen et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Effects of incretin-based therapy in patients with heart failure and myocardial infarction
Nasser Mikhail
ENDOCRINE (2014)
A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Eduard Montanya
EXPERT OPINION ON PHARMACOTHERAPY (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Glycemic Management of Type 2 Diabetes Mellitus
Faramarz Ismail-Beigi
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Management of type 2 diabetes: new and future developments in treatment
Abd A. Tahrani et al.
LANCET (2011)
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications
S. Lesven et al.
ANNALES D ENDOCRINOLOGIE (2010)
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
Kevin M. Pantalone et al.
ACTA DIABETOLOGICA (2009)
Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects
R. E. Steinert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The effects of glucagon-like peptide-1 on the beta cell
T. Vilsboll
DIABETES OBESITY & METABOLISM (2009)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Management of Type 2 diabetes: the role of incretin mimetics
Anthony H. Stonehouse et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K primary care setting
S Maru et al.
DIABETES CARE (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study
TE Delea et al.
DIABETES CARE (2003)
beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
AE Butler et al.
DIABETES (2003)
Share Paper
